Correlation Between Lifecore Biomedical and Neurocrine Biosciences

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Lifecore Biomedical and Neurocrine Biosciences at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Lifecore Biomedical and Neurocrine Biosciences into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Lifecore Biomedical and Neurocrine Biosciences, you can compare the effects of market volatilities on Lifecore Biomedical and Neurocrine Biosciences and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Lifecore Biomedical with a short position of Neurocrine Biosciences. Check out your portfolio center. Please also check ongoing floating volatility patterns of Lifecore Biomedical and Neurocrine Biosciences.

Diversification Opportunities for Lifecore Biomedical and Neurocrine Biosciences

0.39
  Correlation Coefficient

Weak diversification

The 3 months correlation between Lifecore and Neurocrine is 0.39. Overlapping area represents the amount of risk that can be diversified away by holding Lifecore Biomedical and Neurocrine Biosciences in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Neurocrine Biosciences and Lifecore Biomedical is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Lifecore Biomedical are associated (or correlated) with Neurocrine Biosciences. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Neurocrine Biosciences has no effect on the direction of Lifecore Biomedical i.e., Lifecore Biomedical and Neurocrine Biosciences go up and down completely randomly.

Pair Corralation between Lifecore Biomedical and Neurocrine Biosciences

Given the investment horizon of 90 days Lifecore Biomedical is expected to generate 2.07 times more return on investment than Neurocrine Biosciences. However, Lifecore Biomedical is 2.07 times more volatile than Neurocrine Biosciences. It trades about 0.09 of its potential returns per unit of risk. Neurocrine Biosciences is currently generating about -0.06 per unit of risk. If you would invest  575.00  in Lifecore Biomedical on August 16, 2024 and sell it today you would earn a total of  134.00  from holding Lifecore Biomedical or generate 23.3% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Lifecore Biomedical  vs.  Neurocrine Biosciences

 Performance 
       Timeline  
Lifecore Biomedical 

Risk-Adjusted Performance

6 of 100

 
Weak
 
Strong
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Lifecore Biomedical are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak fundamental indicators, Lifecore Biomedical reported solid returns over the last few months and may actually be approaching a breakup point.
Neurocrine Biosciences 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Neurocrine Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's forward indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors.

Lifecore Biomedical and Neurocrine Biosciences Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Lifecore Biomedical and Neurocrine Biosciences

The main advantage of trading using opposite Lifecore Biomedical and Neurocrine Biosciences positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Lifecore Biomedical position performs unexpectedly, Neurocrine Biosciences can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neurocrine Biosciences will offset losses from the drop in Neurocrine Biosciences' long position.
The idea behind Lifecore Biomedical and Neurocrine Biosciences pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.

Other Complementary Tools

Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance